


	Substance briefing: α-PBP
	This technical folder provides information on α-PBP . The information provided is based on a number of existing data sources and work undertaken as part of the I-TREND project. Research informing the folder includes an analysis of user discussions on popular (insert country name) drug forums, an analysis of marketing on popular (insert country name: e.g. English speaking) web shops selling the substance, and scientific laboratory analysis of the compound through test purchasing of the substance from (insert country name) web shops.
1	Substance name(s)
1.1	Chemical name: α -Pyrrolidinobutiophenone
1.2	Popular/street/slangname(s): Users on Czech forums do not have a slang/street/ popular name for this substance
1.3	Other name(s): (RS)-1-Phenyl-2-(1-pyrrolidiny)-1-butanone
1.4	Branded products in which the substance was found following analysis:
1.5	Branded products advertised as containing the substance on web shops: product 1 (shop) product 2 (shop)
1.6	Branded products discussed as containing the substance on drug forums: No branded products were discussed as containing α -PBP
2.	Classification and effect

2.1	<p>Classification and effect confirmed through substance analysis</p> <ul style="list-style-type: none"> • Phenethylamine • Cathinones • Piperazine • Tryptamines • Cannabinoids • Opioids • Aminocyclohexanes • Aminoindanes • Arylalkylamines • Benzodiazepines • Piperidines and pyrrolidines • Other
2.2	<p>Classification and effect referred to by users of drug forums</p> <ul style="list-style-type: none"> • Not discussed at Czeef forums.
2.3	<p>Classification and effect used in the marketing of the product on web shops</p> <ul style="list-style-type: none"> • Phenethylamine • Cathinones • Piperazine • Tryptamines • Cannabinoids • Opioids • Aminocyclohexanes • Aminoindanes • Arylalkylamines • Benzodiazepines • Piperidines and pyrrolidines • Other <p>NB: See reference list for sources related to classification (e.g. pharmacological studies, case studies, etc...)</p>
3	<p>Potential risks associated with use of the substance</p>
3.1	<p>General risks associated with the substance:</p> <p>Unpleasant psychological effects:</p>

	<ul style="list-style-type: none"> • <p>Unpleasant physical effects:</p> <ul style="list-style-type: none"> • <p>Assumed risks due to similarity to other substances:</p> <ul style="list-style-type: none"> • 								
3.2	<p>Users point of view on the substance and risk perception:</p> <p>α-PBP was not discussed on Czech forums, therefore risk perception of users could not be assumed from this source.</p>								
4	Legal status and identification of the substance								
4.1	Legal status/acts/laws in (insert country name)								
4.2	<p>List of first identification and reporting to the EMCDDA by a national Reitox Focal Points</p> <table border="1" data-bbox="331 1093 979 1323"> <thead> <tr> <th>Country</th> <th>Dates</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Country	Dates						
Country	Dates								
5	Photographs of the substance								
5.1	Photograph of the substance purchased for laboratory analysis:								
5.2	Photo/Printscreen of the product from the webshop:								
6	Chemistry								
6.1	Chemical Abstracts Service (CAS) registry number: 13415-54-8								
6.2	Chemical information:								
6.2	Structure (picture of structural formula)								



6.3	Molecular mass 217.306 g/mol																														
6.4	Structural comparison with a related substance																														
6.5	(Insert pictures of developed formula of this original substance)																														
7	Analytical composition: results of substance analysis carried out from the sample purchased online.																														
7.1	<p>Details of laboratory analysis technique used:</p> <p>Mean (%) = (sd.= .) (N sample analysed)</p> <table border="1"> <thead> <tr> <th>Webshop</th> <th>Country (IP address)</th> <th>Country (package origin)</th> <th>Form</th> <th>Substance named on package/webshop</th> <th>Confirmed substances</th> </tr> </thead> <tbody> <tr> <td>1</td> <td></td> <td></td> <td></td> <td>benzofury</td> <td>6 APB</td> </tr> <tr> <td>1</td> <td></td> <td></td> <td></td> <td>Mephedrone</td> <td>Mephedrone</td> </tr> <tr> <td>2</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>2</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>	Webshop	Country (IP address)	Country (package origin)	Form	Substance named on package/webshop	Confirmed substances	1				benzofury	6 APB	1				Mephedrone	Mephedrone	2						2					
Webshop	Country (IP address)	Country (package origin)	Form	Substance named on package/webshop	Confirmed substances																										
1				benzofury	6 APB																										
1				Mephedrone	Mephedrone																										
2																															
2																															
7.2	Details of laboratory analysis technique used:																														
7.3	<p>Substance marketing details</p> <p>SOLD IN: powder, capsule</p> <p>Powder</p>																														

		National currency	Per quantity
	Minimum price		
	Maximum price		
Capsules / tablets / blisters (check what applies)			
		National currency	Per quantity
	Minimum price		
	Maximum price		
Liquids (ml)			
		National currency	Per quantity
	Minimum price		
	Maximum price		
8	Price and marketing strategies on (insert country name) web shops selling the substance		
8.1			
8.2	Description of availability and marketing strategies on (insert country name) web shops selling the substance:		
8.3	Type of (insert country name) websites selling the product		
		No of shops (date)	
	RC shops	product, shop name??	
	Commercial shops		
	Other		
8.4	Number of webshops available for (project partner country) with supposed country of origin in the EU selling the products		
9	Law enforcement and health data		
9.1	Number of law enforcement seizures in (insert country name) in 2013/2014		

9.2	EMCDDA health alerts in (insert country name)
9.2	Confirmed deaths and acute cases reported in (insert country name)
10	<p><u>User experiences of the substance: results from an analysis of discussions (insert country names) Drug Forums</u></p> <p>Methodological comment: The information below is based on an analysis of 0 drug forums, 0 forum posts and 0 forum users.</p>
10.1	<p>Dosage specified by drug forum users (n = number of quotations)</p> <ul style="list-style-type: none"> • <i>Initial Dosing: There was no discussion on initial dose (n= 0)</i> • <i>Boosting: There was no discussion on boosting dose (n= 0)</i> • <i>Threshold: There was no discussion on threshold dose (n= 0)</i> • <i>Light: There was no discussion on light dose (n= 0)</i> • <i>Common: There was no discussion on common dose (n= 0)</i> • <i>Strong: There was no discussion on strong dose (n= 0)</i>
10.2	<p>Duration</p> <ul style="list-style-type: none"> • <i>Onset: There was no discussion on onset time (n =0)</i> • <i>Coming up: There was no discussion on coming up(n =0)</i> • <i>Plateau: There was no discussion on plateau (n =0)</i> • <i>Coming down: There was no discussion on coming down (n =0)</i> • <i>After effects: There was no discussion on plateau (n =0)</i> • <i>Hangover/Day after : There was no discussion on hangover (n =0)</i>
10.3	<p>Effects reported by forum users (n = 1)</p> <p><i>Physical effects</i></p> <ul style="list-style-type: none"> ○ <i>Not discussed in Czech forums</i> <p><i>Psychological effects</i></p> <ul style="list-style-type: none"> ○ <i>Not discussed in Czech forums</i> <p><i>Sought/expected</i></p> <ul style="list-style-type: none"> ○ <i>Not discussed in Czech forums</i> <p><i>Desired</i></p>

	<ul style="list-style-type: none"> ○ <i>Not discussed in Czech forums</i> <i>Undesired</i> ○ <i>Not discussed in Czech forums</i>
10.4	<p>Tolerance <i>Tolerance was not discussed in Czech drug forums.</i></p>
10.5	<p>Route of administration (n =0)</p> <ul style="list-style-type: none"> ● <i>Ingestion: This ROA of α-PBP was not mentioned in Czech drug forums (n =0)</i> ● <i>Snorting: This ROA of α-PBP was not mentioned in Czech drug forums (n =0)</i> ● <i>Rectal: This ROA of α-PBP was not mentioned in Czech drug forums (n =0)</i> ● <i>Inhalation or insufflation: This ROA of α-PBP was not mentioned in Czech drug forums (n =0)</i>
10.6	<p>Others substances referred to in discussion about (insert drug name)</p> <ul style="list-style-type: none"> ● <i>Referred to in comparing the effects : Not mentioned on Czech drug forums (n =0)</i> ● <i>Referred to as increasing the effects: Not mentioned on Czech drug forums (n =0)</i> ● <i>Referred to in managing come down: Not mentioned on Czech drug forums (n =0)</i> ● <i>Other substance discussed in the same episode/combo: Not mentioned on Czech drug forums (n =0)</i> ● <i>Referred to as an agonist/ antagonist : Not mentioned on Czech drug forums (n =0)</i>
10.7	<p>Appearance and preparation (n =0) Not mentioned on Czech drug forums (n =0)</p>
10.8	<p>Patterns of use/Frequency of use</p> <ul style="list-style-type: none"> ● <i>Not mentioned on Czech drug forums (n =0)</i>

10.9	Context of consumption <ul style="list-style-type: none"> o <i>Not mentioned on Czech drug forums (n =0)</i>
10.10	User's views and experiences on the online market <ul style="list-style-type: none"> o <i>Not mentioned on Czech drug forums (n =0)</i>
10.11	Harm reduction Message <ul style="list-style-type: none"> o <i>Not mentioned on Czech drug forums (n =0)</i>
10.12	User profile <i>Effects, experiences and dosages of α-PBP were not discussed.</i>
11	Useful resources and literature <ul style="list-style-type: none"> ▪ http://en.wikipedia.org/wiki/Alpha-Pyrrolidinobutiophenone